


The background of the slide features a close-up, top-down view of several pills and a stethoscope. The pills are in various colors: white, yellow, and pink/red. Some are oval-shaped, while others are capsules. A silver stethoscope with a brown leather-like handle is positioned on the right side, its chest piece resting on a yellow pill. The overall lighting is soft and clinical.

# Bakers Union and FELRA Health and Welfare Fund

Quarterly Review  
January – September 2024

December 12, 2024

## Today's Topics

1. Key Discussion Topics
2. Performance Summary
3. Trend
4. Top Disease States
5. Rebates
6. Clinical Outcomes
  - UM Outcomes
  - Variable Copay Outcomes
  - Vigilant Outcomes

## Your OptumRx Team

### **Marissa Furneaux, MBA**

Sr. Director, Client Management  
Labor & Trust –Western Division

### **Holly Agoney**

Strategic Account Executive  
Labor & Trust

### **Araceli “Shellie” Aldaco**

Pharmacy Account  
Manager  
Labor & Trust

### **David Payton**

CARES Specialist  
Labor & Trust

# Current Plan Design

## ☐ Deductible, Ben Max, MOOP, Copays

| Plan 1 (group BFWRX): |                                                       |
|-----------------------|-------------------------------------------------------|
| Deductible:           | This plan has no deductible.                          |
| Benefit Maximum:      | \$2,000 per year for Growth Hormones medications only |
| Max out of Pocket:    | \$2,850 Individual / \$5,700 Family                   |

| Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3): |                                                       |
|------------------------------------------------|-------------------------------------------------------|
| Deductible:                                    | This plan has no deductible.                          |
| Benefit Maximum:                               | \$2,000 per year for Growth Hormones medications only |
| Max out of Pocket:                             | \$1,850 Individual / \$3,700 Family                   |

## Co-pays

| Plan 1 (group BFWRX) & Plan 2 (group BFWRX2): |                            |            |                 |
|-----------------------------------------------|----------------------------|------------|-----------------|
|                                               | Retail                     |            | Mail            |
| *Generic:                                     | \$10                       | *Generic:  | \$20            |
| *Brand:                                       | \$15                       | *Brand:    | \$30            |
| *NP Brand:                                    | \$30                       | *NP Brand: | \$60            |
| *Specialty:                                   | Run trial claim for co-pay |            | *Specialty: N/A |

## ☐ Effective 7/1/19

- ☐ Diabetes Program
- ☐ Comprehensive Ums
- ☐ Vigilant Program
- ☐ RxOTC Program

## ☐ Effective 8/1/2020

- ☐ Orphan Drug Program

## ☐ Effective 3/1/2021

- ☐ Opioid Mgmt – tighter refill window & Ums

## ☐ Effective 7/1/2021

- ☐ Premium Formulary
- ☐ Mandatory Mail (MSS)

| Plan 3 (group BFWRX3): |                            |             |
|------------------------|----------------------------|-------------|
|                        | Retail / Mail              |             |
| *Generic:              | 5%                         | (\$5 min.)  |
| *Brand:                | 15%                        | (\$15 min.) |
| *NP Brand:             | 25%                        | (\$25 min.) |
| *Specialty:            | Run trial claim for co-pay |             |

## ☐ Effective 1/1/2022

- ☐ Split-fill/Smart-fill

## ☐ Effective 3/1/2022

- ☐ CCAA/VCS

## ☐ Effective 5/15/23

- ☐ Price Edge

# Key Discussion Topics

- ❑ Per Member Per Month (PMPM)
  - ❑ Overall trend = 3.7%
  - ❑ Specialty trend = negative -(26.3)%
- ❑ Specialty represents 0.7% of claims
  
- ❑ Top 5 disease states accounted for 69% of total plan paid
  - ❑ Top traditional disease state: Diabetes
  - ❑ Top specialty disease state: Inflammatory Conditions
  
- ❑ Rebates – Jan – Sept 2024
  - ❑ Estimated - \$209,100
  
- ❑ Clinical Outcomes savings
  - ❑ **UM (PA, ST, QL)** – Oct 2023 – Sept 2024
    - ❑ Savings = \$155,900
  - ❑ **Variable Copay** – Jan – Sept 2024
    - ❑ Savings = \$10,830
  - ❑ **Vigilant** – Oct 2023 – Sept 2024
    - ❑ Savings = \$38,881

# Key Statistics

# Key Statistics – Overall Performance Summary

545

Avg. eligible members

## Key statistics with benchmark comparison

Comparing metrics to benchmarks help showcase areas of focus.

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL

- Client trend was 3.7%, compared to the benchmark trend of 9.5%
- Member Paid Share changed by 11.3% period over period, compared to the benchmark of -9.8%

the benchmark of -9.8%

|                                | LABOR AND TRUST |          |                | COMMERCIAL |                |          |                |
|--------------------------------|-----------------|----------|----------------|------------|----------------|----------|----------------|
| Key statistics                 | Curr            | Prev     | Percent change | Curr       | Percent change | Curr     | Percent change |
| Average age                    | 45.2            | 44.0     | 2.5%           | 38.5       | -0.7%          | 35.8     | -0.1%          |
| Plan paid PMPM                 | \$177.67        | \$171.29 | 3.7%           | \$130.03   | 9.5%           | \$153.85 | 11.3%          |
| Plan paid per Rx               | \$180.16        | \$172.02 | -8.9%          | \$178.31   | 8.1%           | \$191.79 | 8.6%           |
| Rxs PMPM                       | 1.109           | 0.996    | 11.4%          | 0.729      | 1.2%           | 0.802    | 2.5%           |
| Average days supply            | 31.4            | 30.9     | 1.6%           | 41.5       | 0.2%           | 40.5     | -0.2%          |
| Days supply PMPM               | 34.9            | 30.8     | 13.2%          | 30.3       | 1.5%           | 32.5     | 2.3%           |
| Member paid share              | 7.6%            | 6.8%     | 11.3%          | 7.3%       | -9.8%          | 10.5%    | -4.4%          |
| Member paid per Rx             | \$13.09         | \$12.53  | 4.5%           | \$14.05    | -3.3%          | \$22.58  | 3.3%           |
| Generic dispensing rate        | 85.2%           | 84.3%    | 1.0%           | 88.3%      | 0.4%           | 87.3%    | 0.7%           |
| GDR-without Vaccines           | 86.9%           | 86.1%    | 0.9%           | 89.1%      | 0.5%           | 88.4%    | 0.8%           |
| Home delivery rate             | 6.5%            | 6.3%     | 4.5%           | 10.3%      | -2.4%          | 6.2%     | 1.9%           |
| Retail 90 rate                 | 2.1%            | 1.8%     | 14.5%          | 17.2%      | 3.2%           | 20.0%    | -1.2%          |
| Percent of specialty plan paid | 30.2%           | 42.5%    | -28.9%         | 45.6%      | 4.7%           | 51.0%    | 2.3%           |

Total Rxs

CURRENT  
5,437

PREVIOUS  
5,188

PERCENT CHANGE  
4.8%

Total plan paid

CURRENT  
\$870,781

PREVIOUS  
\$892,430

PERCENT CHANGE  
-2.4%

Utilizers

CURRENT  
357

PREVIOUS  
388

PERCENT CHANGE  
-8.0%

# Specialty Key Statistics

## Key statistics with benchmark comparison

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was -26.3%, compared to the benchmark trend of 14.6%
- Member Paid Share changed by 74.3% period over period, compared to the benchmark of -14.7%

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL

| the benchmark of -14.7% |            |            |                | LABOR AND TRUST |                | COMMERCIAL |                |
|-------------------------|------------|------------|----------------|-----------------|----------------|------------|----------------|
| Key statistics          | Curr       | Prev       | Percent change | Curr            | Percent change | Curr       | Percent change |
| Plan Paid PMPM          | \$53.71    | \$72.86    | -26.3%         | \$59.26         | 14.6%          | \$78.43    | 13.9%          |
| Plan paid per Rx        | \$6,580.40 | \$7,029.57 | -6.4%          | \$8,447.68      | 4.3%           | \$7,928.93 | 3.6%           |
| Rxs PMPM                | 0.008      | 0.010      | -21.3%         | 0.007           | 9.8%           | 0.010      | 9.9%           |
| Average days supply     | 32.4       | 31.5       | 2.6%           | 32.4            | 1.5%           | 31.3       | 1.0%           |
| Days supply PMPM        | 0.3        | 0.3        | -19.2%         | 0.2             | 11.5%          | 0.3        | 11.1%          |
| Member paid share       | 4.1%       | 2.4%       | 74.3%          | 3.3%            | -14.7%         | 5.4%       | -3.9%          |
| Member paid per Rx      | \$281.25   | \$169.33   | 66.1%          | \$292.24        | -11.5%         | \$452.41   | -0.7%          |
| Generic dispensing rate | 0.0%       | 0.0%       | 0.0%           | 8.9%            | 1.8%           | 7.6%       | -3.3%          |
| Home delivery rate      | 0.0%       | 1.9%       | -100.0%        | 0.6%            | -84.1%         | 0.3%       | -86.8%         |
| Retail 90 rate          | 7.5%       | 5.6%       | 35.0%          | 5.3%            | 10.9%          | 4.6%       | 5.0%           |

Total Rx's

CURRENT

40

PREVIOUS

54

PERCENT CHANGE

-25.9%

Total plan paid

CURRENT

\$263,216

PREVIOUS

\$379,597

PERCENT CHANGE

-30.7%

Utilizers

CURRENT

7

PREVIOUS

8

PERCENT CHANGE

-12.5%

# Trend Summary


# Trend Summary

**Total Plan Paid PMPM: \$177.67**

## Trend

Plan paid PMPM has increased 3.7% over the previous period driven primarily by drug mix in traditional and utilization for specialty.

Specialty represents 0.7% of claims.



-5.7% under benchmark




+20.4% over benchmark



-40.9% under benchmark

## Plan Paid PMPM

Current period PMPM of \$177.67 equates to \$870.8K in pharmacy spend. 30.2% of the spend is attributed to specialty medications.



# **Top Disease States & Top 20 Drugs**

# Top Disease States









Total Plan Paid PMPM: \$177.67

Top 5 disease states account for 69% of total Plan Paid

- Diabetes accounts for 27.4% of total plan paid, with trend driven by Drug Mix. MOUNJARO was the top drug
- Inflammatory Conditions accounts for 20.9% of total plan paid, with trend driven by Utilization. DUPIXENT was the top drug

Sort by: Plan Paid



# Top 20 Drugs by Plan Cost

All meds are Brands except indicated with a "G" for generic

Specialty

| Rank       |     |       |                  |                                                               |         |     |                 |                 |                  |                     |                     |                      |          | Trend components |              |       |
|------------|-----|-------|------------------|---------------------------------------------------------------|---------|-----|-----------------|-----------------|------------------|---------------------|---------------------|----------------------|----------|------------------|--------------|-------|
| Cu         | Pv  | Bench | Drug name        | Therapy class                                                 | Utilizr | Rxs | Avg days supply | Total plan paid | Plan paid per Rx | Curr plan paid PMPM | Prev plan paid PMPM | Bench plan paid PMPM | % Trend  | Top driver       | % Top driver |       |
| 1          | 1   | 7     | DUPIXENT         | Chronic Inflammatory Disease                                  | 3       | 25  | 28.0            | \$87,188        | \$3,487.50       | \$17.79             | \$20.35             | \$3.43               | -12.6%   | Utilzn           | -12.9%       |       |
| 2          | 4   | 57    | KISQALI          | Oncology                                                      | 1       | 5   | 28.0            | \$72,930        | \$14,586.04      | \$14.88             | \$11.67             | \$0.34               | 27.6%    | Utilzn           | 32.9%        |       |
| 3          | 3   | 2     | HUMIRA PEN       | Chronic Inflammatory Disease                                  | 1       | 3   | 84.0            | \$64,162        | \$21,387.42      | \$13.09             | \$12.32             | \$6.79               | 6.3%     | Utilzn           | 6.3%         |       |
| 4          | 11  | 4     | MOUNJARO         | GLP-1 Receptor Agonists                                       | 11      | 51  | 35.8            | \$63,574        | \$1,246.54       | \$12.97             | \$3.30              | \$4.34               | 293.3%   | Utilzn           | 279.1%       |       |
| 5          | 20  | 350   | STRIBILD         | HIV-Multiclass Combo                                          | 1       | 10  | 30.0            | \$40,698        | \$4,069.84       | \$8.30              | \$1.65              | \$0.05               | 401.9%   | Utilzn           | 431.5%       |       |
| 6          | 6   | 5     | JARDIANCE        | SGLT-2 Inhibitors & Combos                                    | 13      | 56  | 38.6            | \$38,404        | \$685.79         | \$7.84              | \$5.67              | \$4.09               | 38.3%    | Utilzn           | 41.7%        |       |
| 7          | 7   | 1     | OZEMPIC          | GLP-1 Receptor Agonists                                       | 9       | 25  | 44.7            | \$32,727        | \$1,309.09       | \$6.68              | \$4.87              | \$7.27               | 37.1%    | Utilzn           | 39.5%        |       |
| 8          | -   | 14    | ENBREL SURECLICK | Chronic Inflammatory Disease                                  | 1       | 4   | 28.0            | \$30,724        | \$7,680.99       | \$6.27              | \$0.00              | \$1.68               | -        | -                | -            |       |
| 9          | 22  | 11    | WEGOVY           | GLP-1 Anti-Obesity Agents                                     | 4       | 22  | 28.0            | \$26,412        | \$1,200.55       | \$5.39              | \$1.49              | \$2.02               | 262.2%   | Utilzn           | 285.2%       |       |
| 10         | 13  | 12    | FARXIGA          | SGLT-2 Inhibitors & Combos                                    | 7       | 40  | 30.0            | \$22,279        | \$556.97         | \$4.55              | \$2.49              | \$1.94               | 82.4%    | Utilzn           | 77.2%        |       |
| 11         | 12  | 10    | BIKTARVY         | HIV-Multiclass Combo                                          | 1       | 5   | 30.0            | \$17,655        | \$3,531.00       | \$3.60              | \$2.51              | \$2.36               | 43.5%    | Utilzn           | 32.9%        |       |
| 12         | 21  | 8     | ELIQUIS          | Oral Anticoagulants                                           | 6       | 26  | 30.0            | \$14,588        | \$561.08         | \$2.98              | \$1.51              | \$2.83               | 97.7%    | Utilzn           | 84.3%        |       |
| 13         | 491 | 23    | RYBELSUS         | GLP-1 Receptor Agonists                                       | 3       | 14  | 30.0            | \$13,091        | \$935.10         | \$2.67              | \$0.00              | \$1.01               | 0.0%     | Cost             | 0.0%         |       |
| 14         | 8   | 9     | TRULICITY        | GLP-1 Receptor Agonists                                       | 3       | 11  | 28.0            | \$10,395        | \$945.00         | \$2.12              | \$4.84              | \$2.63               | -56.2%   | Utilzn           | -60.1%       |       |
| 15         | 30  | 89    | DEXCOM G6 SENSOR | Diabetes Monitoring and Testing Supplies                      | 3       | 16  | 52.5            | \$9,680         | \$604.99         | \$1.98              | \$1.17              | \$0.24               | 69.3%    | Utilzn           | 65.4%        |       |
| 16         | 14  | 21    | ENTRESTO         | Angiotensin II Receptor & Natriuretic Peptide Receptor (ARNI) | 3       | 9   | 50.0            | \$9,607         | \$1,067.41       | \$1.96              | \$2.38              | \$1.14               | -17.8%   | Utilzn           | -20.3%       |       |
| 17         | 27  | 19    | XARELTO          | Oral Anticoagulants                                           | 3       | 6   | 90.0            | \$9,320         | \$1,553.32       | \$1.90              | \$1.32              | \$1.28               | 43.8%    | Utilzn           | 36.7%        |       |
| 18         | -   | 222   | TYMLOS           | Osteoporosis Agents                                           | 1       | 3   | 30.0            | \$8,212         | \$2,737.34       | \$1.68              | \$0.00              | \$0.08               | -        | -                | -            |       |
| 19         | 31  | 22    | TRELEGY ELLIPTA  | Inhaled Asthma/COPD Combo                                     | 3       | 13  | 30.0            | \$8,208         | \$631.40         | \$1.67              | \$1.06              | \$1.06               | 58.2%    | Utilzn           | 53.6%        |       |
| 20         | 34  | 319   | SOLIQUA 100/ 33  | Insulin                                                       | 1       | 3   | 90.0            | \$7,827         | \$2,609.12       | \$1.60              | \$0.95              | \$0.05               | 67.4%    | Utilzn           | 59.5%        |       |
| Total      |     |       |                  |                                                               |         | 56  | 347             | 36.5            | \$587,682        | \$1,693.61          | \$119.91            | \$79.54              | \$44.64  | 50.8%            |              | 57.4% |
| Plan Total |     |       |                  |                                                               |         | 357 | 5,437           | 31.4            | \$870,781        | \$160.16            | \$177.67            | \$171.29             | \$130.03 | 3.7%             |              | 13.2% |

# Rebates


# Rebate Performance Summary

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Sep 2024

Benchmark: LABOR AND TRUST

**Current rebate value:** \$42.66 PMPM



## Rebate impact on Plan Paid PMPM

Managing drug spend to a lowest net cost PMPM is achieved through adoption of high performing formulary strategies and driving to lowest net cost products when clinically appropriate. Bakers Union and FELRA Health and Welfare Fund's members adherence to the formulary has earned an offset on PMPM costs, yielding a net plan paid PMPM of \$135.01, versus plan paid PMPM of \$177.67.

## Net financial PMPM performance

|             | Drug cost | Member Paid | Plan Paid | Rebates | Net plan paid |
|-------------|-----------|-------------|-----------|---------|---------------|
| Traditional | \$136.17  | \$12.22     | \$123.97  | \$31.23 | \$92.74       |
| Specialty   | \$56.00   | \$2.30      | \$53.71   | \$11.43 | \$42.27       |
| Total       | \$192.17  | \$14.52     | \$177.67  | \$42.66 | \$135.01      |

Total estimated rebate yield for reporting period: **\$209.1K**

# Clinical Outcomes

# UM Outcomes

Bakers Union and FELRA Health and Welfare Fund


Outcomes date range: Oct 2023 - Sep 2024



**Utilization management savings: \$23.75 PMPM**

Your program savings: **\$155.9K**

Ensuring patients meet appropriate clinical criteria when initiating medication therapy not only helps to ensure that the patient is being treated safely according to guidelines, but also drives significant savings for both Bakers Union and FELRA Health and Welfare Fund and for members. Bakers Union and FELRA Health and Welfare Fund has realized over \$155.9K in savings. Based on a study by OptumRx, leveraging UM strategies that drive members to appropriate and often lower cost medications for treatment can save a member up to \$620 annually in out of pocket copayments.



## Prior authorization

PMPM SAVINGS

**\$6.61**

NUMBER OF MEMBERS IMPACTED

**32**

NUMBER OF INTERVENTIONS

**39**

## Quantity limits

PMPM SAVINGS

**\$11.25**

NUMBER OF MEMBERS IMPACTED

**18**

NUMBER OF INTERVENTIONS

**19**

## Step therapy

PMPM SAVINGS

**\$5.89**

NUMBER OF MEMBERS IMPACTED

**87**

NUMBER OF INTERVENTIONS

**113**

QL savings is based only on Maximum Daily Dose edits.

# Variable Copay (VCS) Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Sep 2024

**Total program savings: \$2.21 PMPM**

## Variable copay program savings outcomes

With the OptumRx Variable Copay program, Bakers Union and FELRA Health and Welfare Fund has realized:

- \$10,830 in Plan Paid savings
- \$1,083.00 average Plan Paid per impacted prescription
- 3 total impacted utilizers

PLAN PAID SAVINGS

**\$10,830**

PLAN PAID SAVINGS PER IMPACTED RX

**\$1,083.00**

Top 5 drugs based on: Plan paid savings

DUPIXENT

IMPACTED RXS

**10**

IMPACTED UTILIZERS

**3**

PLAN PAID SAVINGS

**\$10,830**

# Vigilant Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Oct 2023 - Sep 2024

**Total program savings: \$5.92 PMPM**

## Vigilant Drug Outcomes – Cost Avoidance

By leveraging the Vigilant Drug Program, Bakers Union and FELRA Health and Welfare Fund has:

- Avoided \$38.9K in pharmacy spend
- Switched 10 claims to lower cost alternatives
- 6 claims were abandoned



TOTAL PLAN PAID SAVINGS

**\$38,881**

TOTAL PROGRAM SAVINGS

**3.3%**

TOTAL MEMBERS IMPACTED

**15**

## Savings by Vigilant Drug List


Sort by: Members impacted Plan paid PMPM savings

| Vigilant drug list             | PMPM savings | Members impacted | Interventions |
|--------------------------------|--------------|------------------|---------------|
| Clinical Duplicates            | \$0.48       | 8                | 9             |
| High Cost Brands with Generics | \$5.71       | 3                | 3             |
| New Drugs to Market            | -\$0.36      | 3                | 3             |
| Creams & Patches               | \$0.08       | 1                | 1             |

# Appendix

# Selected generic launches in 4Q 2024 through 3Q 2025

\*\*Fund has current utilization in red\*\*



† Generic has 180-days of exclusivity  
\* Xarelto 2.5 mg has potential to launch in 2025; 10 mg, 15 mg, and 20 mg likely won't launch until 2027

# Top 20 traditional

All meds are Brands except indicated with a “G” for generic

| Rank       |      |         | Trend components |                                                       |          |       |                   |                   |                    |                       |                       |                        |           |              |                |
|------------|------|---------|------------------|-------------------------------------------------------|----------|-------|-------------------|-------------------|--------------------|-----------------------|-----------------------|------------------------|-----------|--------------|----------------|
| Cu ↕       | Pv ↕ | Bench ↕ | Drug name ↕      | Therapy class ↕                                       | Utilzr ↕ | Rxs ↕ | Avg days supply ↕ | Total plan paid ↕ | Plan paid per Rx ↕ | Curr plan paid PMPM ↕ | Prev plan paid PMPM ↕ | Bench plan paid PMPM ↕ | % Trend ↕ | Top driver ↕ | % Top driver ↕ |
| 1          | 5    | 2       | MOUNJARO         | ★ GLP-1 Receptor Agonists                             | 11       | 51    | 35.8              | \$63,574          | \$1,246.54         | \$12.97               | \$3.30                | \$4.34                 | 293.3%    | Utilzn       | 279.1%         |
| 2          | 13   | 182     | STRIBILD         | HIV-Multiclass Combo                                  | 1        | 10    | 30.0              | \$40,698          | \$4,069.84         | \$8.30                | \$1.65                | \$0.05                 | 401.9%    | Utilzn       | 431.5%         |
| 3          | 1    | 3       | JARDIANCE        | ★ SGLT-2 Inhibitors & Combos                          | 13       | 56    | 38.6              | \$38,404          | \$685.79           | \$7.84                | \$5.67                | \$4.09                 | 38.3%     | Utilzn       | 41.7%          |
| 4          | 2    | 1       | OZEMPIC          | ★ GLP-1 Receptor Agonists                             | 9        | 25    | 44.7              | \$32,727          | \$1,309.09         | \$6.68                | \$4.87                | \$7.27                 | 37.1%     | Utilzn       | 39.5%          |
| 5          | 15   | 7       | WEGOVY           | GLP-1 Anti-Obesity Agents                             | 4        | 22    | 28.0              | \$26,412          | \$1,200.55         | \$5.39                | \$1.49                | \$2.02                 | 262.2%    | Utilzn       | 285.2%         |
| 6          | 7    | 8       | FARXIGA          | ★ SGLT-2 Inhibitors & Combos                          | 7        | 40    | 30.0              | \$22,279          | \$556.97           | \$4.55                | \$2.49                | \$1.94                 | 82.4%     | Utilzn       | 77.2%          |
| 7          | 6    | 6       | BIKTARVY         | HIV-Multiclass Combo                                  | 1        | 5     | 30.0              | \$17,655          | \$3,531.00         | \$3.60                | \$2.51                | \$2.36                 | 43.5%     | Utilzn       | 32.9%          |
| 8          | 14   | 4       | ELIQUIS          | Oral Anticoagulants                                   | 6        | 26    | 30.0              | \$14,588          | \$561.08           | \$2.98                | \$1.51                | \$2.83                 | 97.7%     | Utilzn       | 84.3%          |
| 9          | 482  | 13      | RYBELSUS         | ★ GLP-1 Receptor Agonists                             | 3        | 14    | 30.0              | \$13,091          | \$935.10           | \$2.67                | \$0.00                | \$1.01                 | 0.0%      | Cost         | 0.0%           |
| 10         | 3    | 5       | TRULICITY        | ★ GLP-1 Receptor Agonists                             | 3        | 11    | 28.0              | \$10,395          | \$945.00           | \$2.12                | \$4.84                | \$2.63                 | -56.2%    | Utilzn       | -60.1%         |
| 11         | 22   | 43      | DEXCOM G6 SENSOR | ★ Diabetes Monitoring and Testing Supplies            | 3        | 16    | 52.5              | \$9,680           | \$604.99           | \$1.98                | \$1.17                | \$0.24                 | 69.3%     | Utilzn       | 65.4%          |
| 12         | 8    | 11      | ENTRESTO         | Angiotensin II Receptor & Neprilysin Inhibitor (ARNI) | 3        | 9     | 50.0              | \$9,607           | \$1,067.41         | \$1.96                | \$2.38                | \$1.14                 | -17.8%    | Utilzn       | -20.3%         |
| 13         | 19   | 10      | XARELTO          | Oral Anticoagulants                                   | 3        | 6     | 90.0              | \$9,320           | \$1,553.32         | \$1.90                | \$1.32                | \$1.28                 | 43.8%     | Utilzn       | 36.7%          |
| 14         | 23   | 12      | TRELEGY ELLIPTA  | Inhaled Asthma/COPD Combo                             | 3        | 13    | 30.0              | \$8,208           | \$631.40           | \$1.67                | \$1.06                | \$1.06                 | 58.2%     | Utilzn       | 53.6%          |
| 15         | 26   | 166     | SOLIQUA 100/ 33  | ★ Insulin                                             | 1        | 3     | 90.0              | \$7,827           | \$2,609.12         | \$1.60                | \$0.95                | \$0.05                 | 67.4%     | Utilzn       | 59.5%          |
| 16         | -    | 439     | SANTYL           | Enzymes - Topical                                     | 1        | 1     | 30.0              | \$7,687           | \$7,687.26         | \$1.57                | \$0.00                | \$0.02                 | -         | -            | -              |
| 17         | -    | 24      | GENVOYA          | HIV-Multiclass Combo                                  | 1        | 1     | 60.0              | \$7,168           | \$7,168.28         | \$1.46                | \$0.00                | \$0.39                 | -         | -            | -              |
| 18         | 285  | 14      | PAXLOVID         | Misc. Antivirals                                      | 8        | 5     | 0.0               | \$5,462           | \$1,092.32         | \$1.11                | \$0.02                | \$0.97                 | 6,043.9%  | Cost         | 6,145.0%       |
| 19         | 90   | 222     | AUVELITY         | Antidepressants                                       | 1        | 5     | 30.0              | \$5,305           | \$1,060.92         | \$1.08                | \$0.19                | \$0.04                 | 463.8%    | Utilzn       | 431.5%         |
| 20         | 59   | 48      | SYNJARDY XR      | ★ SGLT-2 Inhibitors & Combos                          | 2        | 11    | 30.0              | \$5,241           | \$476.43           | \$1.07                | \$0.33                | \$0.22                 | 226.8%    | Utilzn       | 289.8%         |
| Total      |      |         |                  |                                                       | 58       | 330   | 36.2              | \$355,328         | \$1,076.75         | \$72.50               | \$35.75               | \$33.95                | 102.8%    |              | 69.2%          |
| Plan Total |      |         |                  |                                                       | 357      | 5,397 | 31.4              | \$607,565         | \$112.57           | \$123.97              | \$98.43               | \$70.77                | 25.9%     |              | 13.5%          |

# Top 20 specialty

All meds are Brands except indicated with a “G” for generic

| Rank       |    |       | Trend components |                              |         |     |                 |                 |                  |                     |                     |                      |         |            |              |
|------------|----|-------|------------------|------------------------------|---------|-----|-----------------|-----------------|------------------|---------------------|---------------------|----------------------|---------|------------|--------------|
| Cu         | Pv | Bench | Drug name        | Therapy class                | Utilizr | Rxs | Avg days supply | Total plan paid | Plan paid per Rx | Curr plan paid PMPM | Prev plan paid PMPM | Bench plan paid PMPM | % Trend | Top driver | % Top driver |
| 1          | 1  | 4     | DUPIXENT         | Chronic Inflammatory Disease | 3       | 25  | 28.0            | \$87,188        | \$3,487.50       | \$17.79             | \$20.35             | \$3.43               | -12.6%  | Utilzn     | -12.9%       |
| 2          | 4  | 30    | KISQALI          | Oncology                     | 1       | 5   | 28.0            | \$72,930        | \$14,586.04      | \$14.88             | \$11.67             | \$0.34               | 27.6%   | Utilzn     | 32.9%        |
| 3          | 3  | 1     | HUMIRA PEN       | Chronic Inflammatory Disease | 1       | 3   | 84.0            | \$64,162        | \$21,387.42      | \$13.09             | \$12.32             | \$6.79               | 6.3%    | Utilzn     | 6.3%         |
| 4          | -  | 6     | ENBREL SURECLICK | Chronic Inflammatory Disease | 1       | 4   | 28.0            | \$30,724        | \$7,680.99       | \$6.27              | \$0.00              | \$1.68               | -       | -          | -            |
| 5          | -  | 113   | TYMLOS           | Osteoporosis Agents          | 1       | 3   | 30.0            | \$8,212         | \$2,737.34       | \$1.68              | \$0.00              | \$0.08               | -       | -          | -            |
| Total      |    |       |                  |                              | 7       | 40  | 32.4            | \$263,216       | \$6,580.40       | \$53.71             | \$72.86             | \$20.03              | -26.3%  |            | -19.2%       |
| Plan Total |    |       |                  |                              | 7       | 40  | 32.4            | \$263,216       | \$6,580.40       | \$53.71             | \$72.86             | \$59.26              | -26.3%  |            | -19.2%       |